(Q34040939)

30 July 2017

title

Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study (English)

1 reference

30 July 2017

0 references

Jay M Margolis

1

1 reference

30 July 2017

Robert Fowler

2

1 reference

30 July 2017

Barbara H Johnson

3

1 reference

30 July 2017

Cheryl A Kassed

4

1 reference

30 July 2017

Kristijan Kahler

5

1 reference

30 July 2017

publication date

6 October 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

page(s)

122

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

30 July 2017

1 reference

Review of teriflunomide and its potential in the treatment of multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Disease-modifying agents for multiple sclerosis: recent advances and future prospects

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Comorbidity delays diagnosis and increases disability at diagnosis in MS.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

The importance of maintaining effective therapy in multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes

28 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

28 July 2018

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Defining the clinical course of multiple sclerosis: Results of an international survey

28 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

28 July 2018

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Sex ratio of multiple sclerosis in Canada: a longitudinal study.

28 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Long-term interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Oral laquinimod therapy in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3204236

Comorbidity, socioeconomic status and multiple sclerosis

28 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-11-122

Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21974973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21974973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21974973

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2377-11-122

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference